Literature DB >> 10192786

Impaired inflammatory response to glial cell death in genetically metallothionein-I- and -II-deficient mice.

M Penkowa1, M Giralt, T Moos, P S Thomsen, J Hernández, J Hidalgo.   

Abstract

Metallothionein I+II (MT-I+II) are acute-phase proteins which are upregulated during pathological conditions in the brain. To elucidate the neuropathological importance of MT-I+II, we have examined MT-I+II-deficient mice following ip injection with 6-aminonicotinamide (6-AN). 6-AN is antimetabolic and toxic for bone marrow cells and grey matter astrocytes. In MT+/+ mice, injection with 6-AN resulted in breakdown of the blood-brain barrier (BBB) and absence of GFAP-positive astrocytes in specific grey matter areas of the brain stem. Reactive astrocytosis encircled the damaged grey matter areas, which were heavily infiltrated by microglia/macrophages. The recruitment of hematogenous macrophages was accompanied by leakage of the BBB. The immunoreactivity (ir) of granulocyte-macrophage-colony-stimulating factor (GM-CSF) and the receptor for GM-CSF (GM-CSFrec) was significantly upregulated in astrocytes and microglia/macrophages, respectively. MT-I+IIir was also clearly increased in astrocytes surrounding the damaged areas, while that of the CNS-specific MT isoform, MT-III, was mildly increased in both astrocytes and microglia/macrophages. In MT-/- mice injected with 6-AN, the BBB remained almost intact. The damage to specific grey matter areas was similar to that observed in MT+/+ mice, but reactive astrocytosis, microglia/macrophages infiltration, and GM-CSFir and GM-CSFrecir were clearly reduced in MT-/- mice. In contrast, MT-IIIir was dramatically increased in MT-/- mice. Total zinc decreased and histochemically detectable zinc increased in the brain stem after 6-AN similarly in MT+/+ and MT-/- mice. Bone marrow myeloid monocytes and macrophages were increased as a reaction to 6-AN only in MT+/+ mice. The results demonstrate that the capability of MT-/- mice to mount a normal inflammatory response in the brain is severely attenuated, at least in part because of 6-AN-induced bone marrow affectation, involving MT-I+II for the first time as major factors during CNS tissue damage. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10192786     DOI: 10.1006/exnr.1998.7009

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  6 in total

Review 1.  Metallothionein in the central nervous system: Roles in protection, regeneration and cognition.

Authors:  Adrian K West; Juan Hidalgo; Donnie Eddins; Edward D Levin; Michael Aschner
Journal:  Neurotoxicology       Date:  2008-01-19       Impact factor: 4.294

2.  Metallothioneins and brain injury: What transgenic mice tell us.

Authors:  Juan Hidalgo
Journal:  Environ Health Prev Med       Date:  2004-05       Impact factor: 3.674

3.  Metallothionein-IIA promotes initial neurite elongation and postinjury reactive neurite growth and facilitates healing after focal cortical brain injury.

Authors:  Roger S Chung; James C Vickers; Meng Inn Chuah; Adrian K West
Journal:  J Neurosci       Date:  2003-04-15       Impact factor: 6.167

4.  Increased circulating leukocyte numbers and altered macrophage phenotype correlate with the altered immune response to brain injury in metallothionein (MT)-I/II null mutant mice.

Authors:  Michael W Pankhurst; William Bennett; Matthew T K Kirkcaldie; Adrian K West; Roger S Chung
Journal:  J Neuroinflammation       Date:  2011-12-07       Impact factor: 8.322

5.  Metallothionein (MT) -I and MT-II expression are induced and cause zinc sequestration in the liver after brain injury.

Authors:  Michael W Pankhurst; David A Gell; Chris W Butler; Matthew T K Kirkcaldie; Adrian K West; Roger S Chung
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

Review 6.  Metallothionein 1: A New Spotlight on Inflammatory Diseases.

Authors:  Hanying Dai; Lu Wang; Lingyun Li; Zhong Huang; Liang Ye
Journal:  Front Immunol       Date:  2021-11-05       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.